Construction by artificial intelligence and immunovalidation of hypoallergenic mite allergen Der f 36 vaccine

ConclusionThis study represents the first application of an AI strategy to facilitate the development of a B-cell epitope-based hypoallergenic Der f 36 vaccine, which may become a promising immunotherapy for HDM-allergic patients due to its reduced allergenicity and its high immunogenicity in inducing blocking of IgG.
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research